Study Stopped
insufficient positive samples
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Eye-Covid
1 other identifier
observational
30
1 country
1
Brief Summary
To investigate the presence of SARS-nCoV-2 in the tear film of symptomatic and pauci-symptomatic SARS-nCoV-2 positive patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 11, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 13, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 13, 2020
CompletedFirst Submitted
Initial submission to the registry
March 11, 2021
CompletedFirst Posted
Study publicly available on registry
March 16, 2021
CompletedResults Posted
Study results publicly available
January 24, 2025
CompletedJanuary 24, 2025
June 1, 2022
3 months
March 11, 2021
June 28, 2022
December 17, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
The Presence of SARS-nCoV-2 in the Tear Film of Symptomatic and Pauci-symptomatic SARS-nCoV-2 Positive Patients.
Bilateral conjunctival sampling will be performed on both eyes after the application of a drop of topical anesthesia at least once.
during hospitalization every 3 days until the day of discharge up to 1 month
Study Arms (1)
symptomatic patient
to confirm the detectability of the SARS-nCoV-2 in the tear film of symptomatic patients.
Interventions
Each eye will be sampled with a single, sterile, nylon, flocked swab
Eligibility Criteria
positive test for SARS-nCoV-2 on a nasopharyngeal swab.
You may qualify if:
- Subject needs to be above 18 years old.
- The subject is willing to undergo sampling of the conjunctiva.
- The subject is willing to fill in a questionnaire.
- The subject is fluent in written and verbal Dutch.
- The subject is capable of giving informed consent.
- Applicable for part 1 only: the subject test positive for SARS-nCoV-2 on a nasopharyngeal swab. The time window between a positive nasopharyngeal swab and the first conjunctival swab may be no more than 3 days.
You may not qualify if:
- Allergy to Oxybuprocainehydrochloride
- Pregnancy or lactation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UZ Leuven
Leuven, Vlaams Brabant, 3000, Belgium
Related Publications (1)
Leysen L, Delbeke H, Desmet S, Schauwvlieghe PP, Maes P, Blanckaert G, Matthys E, Joossens M, Casteels I. In search of viable SARS-CoV-2 in the tear film: a prospective clinical study in hospitalized symptomatic patients. Clin Microbiol Infect. 2022 Aug;28(8):1172-1173. doi: 10.1016/j.cmi.2022.03.026. Epub 2022 Mar 31. No abstract available.
PMID: 35367365RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Heleen Delbeke, MD
- Organization
- UZ Leuven
Study Officials
- PRINCIPAL INVESTIGATOR
Delbeke Heleen, MD
UZ Leuven
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 11, 2021
First Posted
March 16, 2021
Study Start
September 11, 2020
Primary Completion
December 13, 2020
Study Completion
December 13, 2020
Last Updated
January 24, 2025
Results First Posted
January 24, 2025
Record last verified: 2022-06